Question explored with the scientific record
linee guida terapia emicrania
The short version: the evidence here is about drug treatments, not vaccines, and it shows triptans work for acute attacks while newer CGRP antibodies reduce monthly migraine days, but the long-term safety data is thin and the trials were funded by the manufacturers.
The retrieved studies cover acute and preventive migraine drugs, not vaccines. For acute attacks, triptans clearly outperform placebo: about 76 in 100 people get headache relief within two hours with injected sumatriptan, compared to 27 in 100 with placebo [2]. Oral triptans like eletriptan 40 mg work better than sumatriptan 100 mg on several measures [4]. For prevention, the CGRP antibody eptinezumab reduces monthly migraine days by about 7 to 8 days in chronic migraine patients, versus about 5 to 6 days with placebo [8]. Fremanezumab, another CGRP antibody, cuts headache days by about 4 to 5 days per month compared to 2.5 days with placebo [7].
But the evidence has serious limits. Every phase 3 trial for eptinezumab and fremanezumab was funded by the manufacturer [6, 7, 8]. The safety data is short-term: the longest eptinezumab study ran 104 weeks open-label with no placebo group, and more than half of patients had adverse events [8]. No trial compared these drugs to a true unmedicated control over years. The CGRP antibodies block a peptide involved in blood vessel function and pain signaling, and their long-term effects on vascular health, pregnancy, and immune function are not established [3]. For children, the placebo response is very high, making drug effects harder to see [5]. The 2019 pediatric guideline emphasizes lifestyle changes and shared decision-making before drugs [1].
| Treatment | 2-hour headache relief | Monthly migraine day reduction | Notes |
|---|---|---|---|
| Sumatriptan injection | 76% | - | Best acute efficacy [2] |
| Oral triptans (eletriptan) | 67% | - | Better than sumatriptan 100 mg [4] |
| Eptinezumab (chronic) | - | -7.7 to -8.2 days | Manufacturer-funded; 104-week safety only open-label [8] |
| Fremanezumab (chronic) | - | -4.3 to -4.6 days | Manufacturer-funded; 12-week trial [7] |
| Placebo | 27% | -5.6 days | Baseline for comparison [2, 8] |
My call: triptans are well-proven for acute attacks, and CGRP antibodies reduce migraine days in the short term, but the long-term safety data is absent or manufacturer-funded. Confidence: moderate for acute triptan efficacy, low for long-term safety of CGRP antibodies.
Sources used 8
-
Practice guideline update summary: Pharmacologic treatment for pediatric migraine prevention
A 2019 practice guideline update by the American Academy of Neurology and American Headache Society systematically reviews pediatric migraine prevention trials to provide evidence-based pharmacologic recommendations (with/without CBT), highlighting a prominent placebo response a…
DOI: 10.1212/WNL.0000000000008105 -
Triptans in the Acute Treatment of Migraine: A Systematic Review and Network Meta‐Analysis
This systematic review and network meta-analysis evaluates the comparative efficacy of triptans for the acute treatment of migraines, finding that standard dose triptans are effective and often outperform other treatments such as ergots and NSAIDs.
DOI: 10.1111/head.12601 -
Epidemiology and Treatment of Menstrual Migraine and Migraine During Pregnancy and Lactation: A Narrative Review
A narrative review detailing how menstrual migraine and migraine across pregnancy and lactation are shaped by hormonal changes, summarizing epidemiology, safety and efficacy of acute and preventive treatments, and hormonal/nonpharmacologic management strategies, while highlighti…
DOI: 10.1111/head.13665 -
The 40‐mg dose of eletriptan: comparative efficacy and tolerability versus sumatriptan 100 mg
A pooled head-to-head comparison of eletriptan 40 mg versus sumatriptan 100 mg in acute migraine treatment across three randomized trials shows eletriptan provides higher efficacy across multiple outcomes (2-h headache response, pain-free, and sustained responses) with comparabl…
DOI: 10.1046/j.1351-5101.2003.00730.x -
Placebo Efficacy in Childhood and Adolescence Migraine: An Analysis of Double-Blind and Placebo-Controlled Studies
A meta-analysis of 41 double-blind, placebo-controlled pediatric migraine trials shows higher placebo responses in parallel-group designs than crossover designs for both acute and prophylactic treatment, implying trial design heavily influences the apparent efficacy of migraine …
DOI: 10.1111/j.1468-2982.2008.01752.x -
Eptinezumab: A calcitonin gene-related peptide monoclonal antibody infusion for migraine prevention
Eptinezumab is an effective and generally well-tolerated preventive treatment for migraine, particularly in chronic migraine and high acute medication users, but its high cost positions it as salvage therapy after failure of oral non-specific preventives.
DOI: 10.1177/20503121211050186 -
Fremanezumab for the Preventive Treatment of Chronic Migraine
This phase 3 trial demonstrated that fremanezumab, a humanized monoclonal antibody targeting CGRP, significantly reduces the frequency of headache days in patients with chronic migraine compared to placebo.
DOI: 10.1056/NEJMoa1709038 -
Eptinezumab for the treatment of migraine
An expert opinion/review evaluating eptinezumab (ALD403) as a quarterly IV preventive treatment for episodic and chronic migraine, detailing its pharmacology, phase 2/3 efficacy/safety data, rapid onset, PK characteristics, and positioning within migraine therapy.
DOI: 10.1080/14712598.2021.1931678